文献速递免疫规划卫生政策与健康促进

瑞士人乳头瘤病毒(HPV)疫苗接种率地区异质性对传播影响的模型研究

Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland.
PubMed 文献 · Vaccine · 2017-11-07

瑞士26个州16岁女性HPV疫苗完成接种率范围为17%至75%。研究建立确定性人群模型模拟HPV-16在州内及州间年轻成人中的传播,比较异质性接种与全国平均接种率52%的同质性接种。结果显示异质性接种下全国HPV-16总体患病率略高于同质性接种,但差异幅度小;接种率低的州可从州间性混合中获益,而接种率高的州则承受相应代价。

要点

  • 瑞士各州16岁女性HPV疫苗完成接种率差异大,范围为17%至75%。
  • 异质性接种15年后女性HPV-16患病率在全国为0.63%,同质性接种为0.59%。
  • 接种率低的州通过州间性混合从高接种率州获益,后者患病率相应升高。

核心结论

  • 接种率地区差异削弱了瑞士HPV疫苗接种对HPV-16患病率的总体效果,但效应量小。
  • 接种率低的州会削弱各州通过提高接种率降低HPV患病率的努力。
  • 协调各州疫苗接种规划将缩小州间HPV-16患病率差异,尽管对全国患病率的预期影响相对较小。

研究设计与样本

  • 确定性、基于人群的模型,描述HPV-16在瑞士26个州内及州间年轻成人中的传播。
  • 模型参数使用瑞士性行为数据和瑞士全国疫苗接种覆盖率调查数据。
  • 先研究两个亚人群间接种率异质性的一般后果,再比较全国异质性接种与接种率等于全国平均52%的同质性接种所预测的HPV-16患病率。

主要发现

  • 基线情景下,引入疫苗接种时女性HPV-16患病率为3.34%,接种15年后各州患病率开始分化,范围为0.19%至1.20%。
  • 接种15年后,异质性接种下瑞士HPV-16总体患病率为0.63%,仅略高于同质性接种的0.59%。
  • 假设存在州间性混合时,接种率低的州从患病率下降中获益,而接种率高的州承受相应代价。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Completed human papillomavirus (HPV) vaccination by age 16 years among women in Switzerland ranges from 17 to 75% across 26 cantons. The consequences of regional heterogeneity in vaccination coverage on transmission and prevalence of HPV-16 are unclear. METHODS: We developed a deterministic, population-based model that describes HPV-16 transmission among young adults within and between the 26 cantons of Switzerland. We parameterized the model using sexual behavior data from Switzerland and data from the Swiss National Vaccination Coverage Survey. First, we investigated the general consequences of heterogeneity in vaccination uptake between two sub-populations. We then compared the predicted prevalence of HPV-16 resulting from heterogeneous HPV vaccination uptake in all of Switzerland with homogeneous vaccination at an uptake that is identical to the national average (52%). RESULTS: In our baseline scenario, HPV-16 prevalence in women is 3.34% when vaccination is introduced and begins to diverge across cantons, ranging from 0.19 to 1.20% after 15 years of vaccination. After the same time period, overall prevalence of HPV-16 in Switzerland is only marginally higher (0.63%) with heterogeneous vaccination uptake than with homogeneous uptake (0.59%). Assuming inter-cantonal sexual mixing, cantons with low vaccination uptake benefit from a reduction in prevalence at the expense of cantons with high vaccination uptake. CONCLUSIONS: Regional variations in uptake diminish the overall effect of vaccination on HPV-16 prevalence in Switzerland, but the effect size is small. Cantonal efforts towards HPV-prevalence reduction by increasing vaccination uptake are impaired by cantons with low vaccination uptake. Although the expected impact on national prevalence would be relatively small, harmonization of cantonal vaccination programs would reduce inter-cantonal differences in HPV-16 prevalence.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Riesen M, Garcia V, Low N, et al. Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland. Vaccine. 2017. PMID: 29126806. doi:10.1016/j.vaccine.2017.10.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。